{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mamounas EP"],"funding":["Korea Health Technology R&amp;D Project","NCI","Biotheranostics Inc","NCI NIH HHS","BCRF","Novartis, which provided letrozole and placebo to all study sites during the course of the study"],"pagination":["1984-1991"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11061597"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(9)"],"pubmed_abstract":["<h4>Purpose</h4>BCI (H/I) has been shown to predict extended endocrine therapy (EET) benefit. We examined BCI (H/I) for EET benefit prediction in NSABP B-42, which evaluated extended letrozole therapy (ELT) in patients with hormone receptor-positive breast cancer after 5 years of ET.<h4>Experimental design</h4>A stratified Cox model was used to analyze RFI as the primary endpoint, with DR, BCFI, and DFS as secondary endpoints. Because of a nonproportional effect of ELT on DR, time-dependent analyses were performed.<h4>Results</h4>The translational cohort included 2,178 patients (45% BCI (H/I)-High, 55% BCI (H/I)-Low). ELT showed an absolute 10-year RFI benefit of 1.6% (P = 0.10), resulting in an underpowered primary analysis (50% power). ELT benefit and BCI (H/I) did not show a significant"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial."],"pmcid":["PMC11061597"],"funding_grant_id":["NCI U10CA 180868","UG1 CA189867","NCI U10CA 180822","BCRF20-147","BCRF 22-147)","BCRF19-147","U24 CA196067","U10 CA180868","U10 CA180822","BCRF 21-147","UG1CA189867"],"pubmed_authors":["Lucas PC","Brufsky AM","Treuner K","Fehrenbacher L","Walshe JM","Paik S","Schnabel CA","Bandos H","Zhang Y","Chia SK","Mamounas EP","Soori GS","Rastogi P","Geyer CE","Dakhil S","Wolmark N","Swain SM","Sgroi DC"],"additional_accession":[]},"is_claimable":false,"name":"Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial.","description":"<h4>Purpose</h4>BCI (H/I) has been shown to predict extended endocrine therapy (EET) benefit. We examined BCI (H/I) for EET benefit prediction in NSABP B-42, which evaluated extended letrozole therapy (ELT) in patients with hormone receptor-positive breast cancer after 5 years of ET.<h4>Experimental design</h4>A stratified Cox model was used to analyze RFI as the primary endpoint, with DR, BCFI, and DFS as secondary endpoints. Because of a nonproportional effect of ELT on DR, time-dependent analyses were performed.<h4>Results</h4>The translational cohort included 2,178 patients (45% BCI (H/I)-High, 55% BCI (H/I)-Low). ELT showed an absolute 10-year RFI benefit of 1.6% (P = 0.10), resulting in an underpowered primary analysis (50% power). ELT benefit and BCI (H/I) did not show a significant","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 May","modification":"2026-06-01T23:50:09.124Z","creation":"2026-05-23T03:08:13.611Z"},"accession":"S-EPMC11061597","cross_references":{"pubmed":["38376912"],"doi":["10.1158/1078-0432.CCR-23-1977"]}}